BackHua Medicine (Shanghai) Overview

Hua Medicine (Shanghai) Receivables

Hua Medicine (Shanghai)'s receivables is $160M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$155.29M
↑ 94.01% YoYΔ $75.25M vs prior year quarter

Peer trimmed avg / median

Loading

Hua Medicine (Shanghai) Receivables History

Loading

Hua Medicine (Shanghai) vs. peers: Receivables Comparison

Loading

Hua Medicine (Shanghai) Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Hua Medicine (Shanghai) (HUMDF) FAQ

Hua Medicine (Shanghai) posts a receivables of $160M as of June 2026. That compares with $80M in the prior-year period — up 94.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Hua Medicine (Shanghai)'s receivables was $80M. The latest reading is $160M — a 94.0% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Hua Medicine (Shanghai)'s financial statement story. At $160M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for HUMDF's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Hua Medicine (Shanghai)'s other metric pages and overview cover the third.